Product Number: L045013
English Name: Lobeline Impurity 13
English Alias: (1S,1'S)-2,2'-((2S,6R)-1-methylpiperidine-2,6-diyl)bis(1-phenylethanol)
CAS Number: 1125824-42-1
Molecular Formula: C₂₂H₂₉NO₂
Molecular Weight: 339.47
As a chiral impurity of lobeline, the research advantages of this compound lie in:
Analyzing the by-product formation mechanism of piperidine ring construction or chiral center formation during lobeline synthesis to optimize processes for controlling stereoisomer impurity generation;
Serving as a chiral reference standard containing bis(phenylethanol) structures to provide a standard substance for detecting chiral impurities in drugs, improving the accuracy of enantiomer separation and detection;
Helping study the impact of piperidine ring and phenylethanol structures on drug activity and metabolism to provide a scientific basis for impurity control strategies.
Drug Development: Used as a chiral impurity reference standard to identify and quantify Impurity 13 in lobeline preparations, evaluating the stereochemical purity of APIs and formulations;
Quality Control: Acting as a standard substance to validate the sensitivity of chiral HPLC or supercritical fluid chromatography (SFC) and other detection methods, ensuring chiral impurity content meets pharmacopoeia requirements during production;
Toxicological Research: Evaluating the potential impact of this chiral impurity on lobeline safety by comparing the biological effects of different configurations.
Lobeline is a respiratory center stimulant clinically used for treating neonatal asphyxia, carbon monoxide poisoning, etc. Its molecular structure contains multiple chiral centers, making it prone to generating stereoisomeric impurities during synthesis. Lobeline Impurity 13, as a bis(phenylethanol) derivative with (2S,6R)-piperidine configuration, may be formed during condensation reactions or chiral induction, and its content directly affects drug quality. Since chiral isomers may have different pharmacological activities or toxicities, research on this impurity is a key part of lobeline quality control.
Current research focuses on:
Chiral Synthesis Processes: Developing highly stereoselective impurity synthesis methods to obtain single-configuration reference standards through chiral catalysts or resolution techniques;
Chiral Detection Technologies: Establishing high-resolution enantiomer separation and detection methods using chiral stationary phase HPLC or LC-MS combined techniques;
Stereoisomeric Effects: Investigating the impact of this impurity on lobeline receptor binding ability and pharmacokinetics through in vitro activity experiments and animal models;
Process Control Strategies: Analyzing the influence of parameters such as reaction temperature and solvent polarity during piperidine ring formation on stereoselectivity to optimize conditions for reducing chiral impurity generation.
China
